Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
sirexatamab (DKN-01)
i
Other names:
DKN-01, LY2812176, LY-2812176, DKN 01, DKN01, LY 2812176
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(12)
News
Trials
Company:
Eli Lilly, Leap Therap
Drug class:
DKK1 protein inhibitor
Related drugs:
‹
BHQ880 (0)
BHQ880 (0)
›
Associations
(12)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer (NCT05761951)
Phase 2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/13/2024
Initiation :
08/29/2023
Primary completion :
01/31/2027
Completion :
01/31/2029
CTNNB1 • AXIN1 • RSPO2 • ZNRF3
|
CTNNB1 mutation
|
Keytruda (pembrolizumab) • sirexatamab (DKN-01)
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish) (NCT04363801)
Phase 2
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
Active, not recruiting
Phase 2
Leap Therapeutics, Inc.
Active, not recruiting
Last update posted :
01/22/2024
Initiation :
07/29/2020
Primary completion :
06/01/2025
Completion :
12/01/2025
PD-L1 • DKK1
|
5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium • sirexatamab (DKN-01)
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (KEYNOTE-731) (NCT02013154)
Phase 1
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
Completed
Phase 1
Leap Therapeutics, Inc.
Completed
Last update posted :
11/01/2023
Initiation :
05/05/2014
Primary completion :
07/19/2019
Completion :
01/11/2021
PD-L1
|
Keytruda (pembrolizumab) • paclitaxel • sirexatamab (DKN-01)
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors (NCT04681248)
Phase N/A
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
Available
Phase N/A
Leap Therapeutics, Inc.
Available
Last update posted :
09/29/2023
RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
|
sirexatamab (DKN-01)
DKN-01 Inhibition in Advanced Liver Cancer (NCT03645980)
Phase 1/2
Johannes Gutenberg University Mainz
Johannes Gutenberg University Mainz
Recruiting
Phase 1/2
Johannes Gutenberg University Mainz
Recruiting
Last update posted :
10/22/2020
Initiation :
10/10/2018
Primary completion :
08/31/2021
Completion :
08/31/2022
PD-1
|
sorafenib • sirexatamab (DKN-01)
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (EORTC 1741-GITCG) (NCT03818997)
Phase 2
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and ...
Withdrawn
Phase 2
European Organisation for Research and Treatmen...
Withdrawn
Last update posted :
02/05/2020
Initiation :
12/01/2019
Primary completion :
04/01/2021
Completion :
04/01/2022
HER-2
|
HER-2 positive
|
cisplatin • Tecentriq (atezolizumab) • paclitaxel • sirexatamab (DKN-01)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login